



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 12 March 2024

OTHER RELEVANT INFORMATION

Laboratorios Farmacéuticos ROVI, S.A. (ROVI), in compliance with the duties set out in article 227 of Law 6/2023 in 17 March on Securities Markets and Investment Services, informs of the agreement reached with the Ministry of Science, Innovation and Universities through Innvierte Economía Sostenible SICC, SME, S.A. (the investment company of *Centro para el Desarrollo Tecnológico Industrial EPE – CDTI*) and Insud Pharma S.L. to incorporate a limited company (*Sociedad de responsabilidad limitada*) with public and private capital. This company will engage in the research and development of advanced therapies within the framework of the Vanguard Health Strategic Project for Economic Recovery and Transformation (PERTE).

Attached hereto is the press release in relation to the foregoing, which will be distributed today and may be accessed through the Company's website.

Yours faithfully

Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A

Press Release

ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies

➤ This public-private collaboration instrument falls within the framework of the Vanguard Health Strategic Project for Economic Recovery and Transformation (PERTE) and will have an initial investment of over 74 million euros

Madrid, 12 March 2024

Laboratorios Farmacéuticos ROVI, S.A. (hereinafter, ROVI), informs of the agreement that has been concluded with Insud Pharma S.L. and Innvierte Economía Sostenible SICCC, SME, S.A. (investment company of *Centro para el Desarrollo Tecnológico Industrial EPE – CDTI*) to incorporate, together with these two entities, a limited company (*Sociedad de responsabilidad limitada*) engaged in the research and development of advanced therapies.

This agreement, which was approved at the meeting of the Council of Ministers held on 12 March 2024, falls within the framework of the Vanguard Health Strategic Project for Economic Recovery and Transformation (PERTE), promoted by the Spanish Government. This PERTE concerns the creation of a public-private investment vehicle to develop advanced, innovative and/or emerging medicines, therapies and/or technologies. The goal is to favour the deployment of the technical and industrial capacities necessary to generate a high-performance healthcare system intended to protect health by

providing an immediate and flexible response to healthcare challenges and favouring sustainability.

The share capital of this new entity will be 49% held by the Ministry of Science, Innovation and Universities through the company Invierte, while Insud Pharma and ROVI will hold 25.5% each. The shareholders undertake to make an initial combined contribution of 74,867,346.94 euros. Further investment will be made in accordance with the needs of the projects defined in the future and will be subject to the shareholders' approval of the relevant business plan. Such investment could reach 220 million euros, which would be contributed by the public and private investors that are participating.

It is planned that Invierte's contributions could be made with European "Next Generation EU" funds, which include the EU Recovery and Resilience Facility established in Regulation (EU) 2921/241 of the European Parliament and of the Council of 12 February 2021.

Juan López-Belmonte, Chairman and CEO of ROVI, highlights the fact that this agreement *"represents an opportunity to help place Spain in a leading position in the clinical research of new therapies, with the capacity to translate this research into manufacturing and thus improve the availability of new therapies to patients. At ROVI, we are delighted to place our knowledge and experience at the service of this great public-private alliance that reinforces our commitment to innovation"*.

About ROVI

ROVI is a pan-European pharmaceutical company specialising and engaging in the research, development, contract manufacturing and licensing of small molecules and biological specialties. The company, in a continuous expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a

diversified marketing portfolio of over 40 products, among which its flagship product, bemiparin, now present in more than 60 countries all over the world, should be highlighted. Likewise, ROVI markets its enoxaparin biosimilar, developed in-house, in Europe and this product is already present in 40 countries. ROVI is continuing to develop the ISM® technology platform, a leading-edge line of research in the field of prolonged drug release, with proven advantages. For more information, please visit www.rovi.es.